| Literature DB >> 32265846 |
Fatima Cody Stanford1,2,3, Tasnim Mushannen1,4, Priscilla Cortez1,5, Karen J Campoverde Reyes1,6, Hang Lee7, Denise W Gee3, Janey S Pratt8, Paul A Boepple2,3, Miriam A Bredella9, Madhusmita Misra1,2, Vibha Singhal1,2,3.
Abstract
Objective: We sought to compare the short and long-term outcomes of MBS in adolescents vs. adults who have undergone a Roux-en-Y gastric bypass (RYGB) or Sleeve gastrectomy (SG). Design: Retrospective cohort study. Setting: Single tertiary care academic referral center. Participants: One hundred fifty adolescent (≤ 21-years) and adult (>21-years) subjects with severe obesity between 15 and 70 years of age who underwent RYGB or SG. Outcomes: Metabolic parameters, weight and height measures were obtained pre-and post-surgery (at 3 and 6 months, and then annually for 4 years).Entities:
Keywords: adolescent; adult; bariatric surgery; obesity complications; obesity surgery; weight loss
Mesh:
Year: 2020 PMID: 32265846 PMCID: PMC7105703 DOI: 10.3389/fendo.2020.00157
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Baseline demographics of the adult and adolescent groups.
| Age | 46.5 (38.0–59.3) | 18.0 (17.3–19.8) | |
| Sex (male/female) | 31/43 | 13/63 | |
| Height (in) | 66.9 ± 4.2 | 65.9 ± 3.1 | 0.080 |
| Weight (Kg) | 127.3 (112.6–151.4) | 140.9 (123.5–158.8) | |
| BMI (Kg/m2) | 43.6 (40.0–51.3) | 50.5 (45.3–56.7) | |
| RYGB (%) | 59.5 | 77.6 | |
| SG (%) | 40.5 | 22.4 | |
| White | 79.7 | 59.2 | 0.080 |
| Hispanic | 12.2 | 22.4 | |
| African-American | 2.7 | 7.9 | |
| Asian | 0 | 3.4 | |
| >1 race | 2.7 | 5.3 | |
| Unknown | 2.7 | 1.3 | |
| Systolic BP (mm Hg) | 129 (118–142) | 126 (117–134) | 0.220 |
| Diastolic BP (mm Hg) | 77 (70.75–82) | 75 (66–83.5) | 0.560 |
| HDL (mg/dL) | 41.5 (36.8–53.0) | 39 (33.5–45.5) | 0.100 |
| LDL (mg/dL) | 108.6 ± 36.5 | 95.9 ± 4.0 | |
| Triglycerides (mg/dL) | 146.5 (99.3–207.8) | 102 (74.5–141.0) | |
| Cholesterol (mg/dL) | 184.5 (159.3–205.5) | 156.0 (140.0–179.0) | |
| Hgb A1c (%) | 6.2 (5.63–7.15) | 5.6 (5.2–5.9) | |
| ALT (IU/L) | 26.0 (16.3–36.0) | 23.0 (17.0–36.0) | 0.760 |
| AST (IU/L) | 23.0 (17.3–29.5) | 22.0 (18.0–27.0) | 0.640 |
| Alkaline phosphatase (IU/L) | 74.0 (59.8–87.5) | 82.5 (66.0–102.0) | |
| TIBC (μg/dL) | 321.6 ± 53.3 | 353.8 ± 61.9 | |
| Iron (μg/dL) | 67.0 (54.3–86.5) | 54.5 (36.3–85.5) | |
| Ferritin (ng/mL) | 85.0 (39.0–168.8) | 56.0 (34.5–81.0) | |
| Vitamin B12 (pg/mL) | 476.5 (349.3–673.5) | 508.0 (396.0–620.0) | 1.000 |
| Vitamin D (ng/ml) | 25.5 (19.0–31.0) | 23.0 (18.0–28.0) | 0.210 |
Wilcoxon Test was used for non-normally distributed data.
TIBC, Total iron binding capacity.
Bold value means statistically significant.
Distribution of pre-surgery weight related complications.
| Hypertension ( | Hypertension ( | |
| Dyslipidemia ( | Dyslipidemia ( | |
| Type 2 Diabetes Mellitus ( | Type 2 Diabetes Mellitus ( | |
| Obstructive Sleep Apnea ( | Obstructive Sleep Apnea ( | 0.845 |
| Y: 36/41 (87.80%) | Y: 35/42 (83.33%) | |
| N: 5/41 (12.20%) | N: 7/42 (16.67%) | |
| 0.085 | ||
| Y: 57/69 (82.61%) | Y: 68/74 (91.89%) | |
| N: 12/69 (17.39%) | N: 6/74 (8.11%) | |
| 0.091 | ||
| Y: 55/69 (79.71%) | Y: 67/74 (90.54%) | |
| N: 14/69 (20.29%) | N: 7/74 (9.46%) | |
| 0.953 | ||
| Y: 27/69 (39.13%) | Y: 26/71 (36.62%) | |
| N: 42/69 (60.87%) | N: 45/71 (63.38%) | |
| 0.305 | ||
| Y: 32/66 (48.48%) | Y: 27/71 (38.03%) | |
| N: 34/66 (51.52%) | N: 44/71 (61.97%) |
NASH, non-alcoholic steatohepatitis. Bold value means statistically significant.
Figure 1Percent of total body weight loss post-surgery over time.
Percent weight loss at different time points stratified by surgery type.
| 3 Months | −15.9 ± 4.8 | −12.0 ± 4.8 | −16.0 ± 4.8 | −16.3 ± 5.3 | 0.843 | 0.939 | ||
| 6 Months | −23.1 ± 6.7 | −17.2 ± 7.8 | −24.4 ± 5.1 | −22.9 ± 4.9 | 0.374 | 0.341 | ||
| 1 Year | −26.7 ± 10.5 | −21.1 ± 9.9 | −30.7 ± 8.9 | −29.2 ± 8.5 | 0.670 | 0.071 | ||
| 2 Years | −30.2 | −19.3 | −33.8 | −24.9 | 0.473 | 0.059 | ||
| 3 Years | −26.5 ± 10.9 ( | −13.6 ± 12.3 ( | −31.0 ± 14.1 ( | −27.9 ± 13.2 ( | 0.601 | 0.172 | ||
| 4 Years | −24.7 ± 11.2 ( | −11.2 ± 12.3 ( | −32.3 | −24.4 | 0.243 | 0.135 | ||
Wilcoxon Test used for non-normally distributed data. Bold value means statistically significant.
Figure 2Proportion of subjects with resolution of hypertension, diabetes, and dyslipidemia.